1326 results about "Primary cell" patented technology

A stabilized vanadium electrolyte solution for use in an all-vanadium redox cell or battery, the stabilized electrolyte solution comprising vanadium redox ions, an electrolyte and a stabilizing agent, wherein precipitation of vanadium redox ions from the electrolyte solution is prevented or reduced by the stabilizing agent when precipitation of the vanadium redox ions would otherwise occur and wherein the stabilizing agent is present in the electrolyte solution at a concentration of from 0.05 to 20% mol / mol of stabilizing agent to vanadium redox ions.

Disclosed is a method for preparing a high energy density (HED) electrolyte solution for use in an all-vanadium redox cells, a high energy density electrolyte solution, in particular an all-vanadium high energy density electrolyte solution, a redox cell, in particular an all-vanadium redox cell, comprising the high energy density electrolyte solution, a redox battery, in particular an all-vanadium redox battery, comprising the HED electrolyte solution, a process for recharging a discharged or partially discharged redox battery, in particular an all-vanadium redox battery, comprising the HED electrolyte solution, a process for the production of electricity from a charged redox battery, and in particular a charged all-vanadium redox battery, comprising the HED electrolyte, a redox battery / fuel cell and a process for the production of electricity from a redox battery / fuel cell. A method for stabilising an electrolyte solution for use in a redox cell, in particular for stabilising an electrolyte solution for use in an all-vanadium redox cell, a stabilised electrolyte solution, in particular an all-vanadium stabilised electrolyte solution, a redox cell, in particular an all-vanadium redox cell, comprising the stabilised electrolyte solution, a redox battery, in particular an all-vanadium redox battery comprising the stabilised electrolyte solution, a process for recharging a discharged or partially discharged redox battery, in particular an all-vanadium redox battery, comprising the stabilised electrolyte solution, and a process for the production of electricity from a charged redox battery, and in particular a charged all-vanadium redox battery, comprising the stabilised electrolyte solution are disclosed. Also disclosed are a redox battery / fuel cell and a process for the production of electricity from a redox battery / fuel cell.

The invention relates to a cellular communication system based on a central main unit, a primary-cell communication unit connected to the central main unit, and a number of secondary-cell communication units. Each secondary-cell unit is connected to the primary-cell unit via a respective wireless optical link. The secondary-cell communication units are preferably remote radio units in a distributed radio base system, where each remote radio unit forms a distributed radio base station together with the central main unit. The wireless optical link quality is measured to detect reduced link availability. The invention compensates for insufficient link availability by providing adequate radio coverage from another communication unit within the cellular system and re-directing the radio traffic to that communication unit. Adequate radio coverage from another communication unit within the cellular system and re-directing the radio traffic to that communication unit. Adequate radio coverage is accomplished either by dynamically increasing the radio coverage or using a micro-macro cell architecture.

A hybrid battery power source for implantable medical use provides a generally constant low internal resistance during discharge and avoids voltage delays of the type that develop as a result of run down-induced resistance increase in Li / SVO cells. The hybrid battery power source utilizes two batteries or cells, one being a primary cell of relatively high energy density and the other being a secondary cell of relatively low internal resistance that is rechargeable. The primary and secondary cells are connected in a parallel arrangement via a voltage boost / charge control circuit that is powered by the primary cell and adapted to charge the secondary cell while limiting charge / discharge excursions thereof in a manner that optimizes its output for high energy medical device use. The energy storage capacitors of the medical device in which the hybrid battery power source is situated are driven by the secondary cell. The primary cell is used to as an energy source for recharging the secondary cell.

The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime / vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.

Described herein are methods of generating a genetically modified cell by providing a zinc finger endonuclease (ZFE) that includes an endonuclease domain that cuts DNA, and a zinc finger domain that includes a plurality of zinc fingers that bind to a specific nucleotide sequence within the endogenous chromosomal target DNA in the primary cell. Further, the methods can include contacting the endogenous chromosomal target DNA sequence with the zinc finger endonuclease in the primary cell such that the zinc finger endonuclease cuts both strands of a nucleotide sequence within the endogenous chromosomal target DNA sequence in the primary cell, thereby enhancing the frequency of homologous recombination in the endogenous chromosomal target DNA sequence.